United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

4:18pm BST
Change (% chg)

$0.33 (+3.06%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

McCarthy, Sean 

Dr. Sean A. McCarthy will be appointing as aChairman of the Board, President, Chief Executive Officer of the company, Effective December 31, 2018. He has served as a member of the board of directors and our president and chief executive officer since August 2011. Previously, Dr. McCarthy has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto), Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium, Dr. McCarthy joined SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as Vice President Business Development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, where he was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy is an author on multiple peer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in biochemistry and pharmacology at King’s College, University of London; an MBA from the Rady School of Management at the University of California San Diego; and a D.Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy currently serves as a member of the Board of Directors of the California Life Sciences Association.

Basic Compensation

Total Annual Compensation, USD 500,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,713,340
Fiscal Year Total, USD 3,213,340

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --